These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2907645)

  • 21. [Therapeutic effects of butyrilperazine].
    Bohacek N
    Neuropsihijatrija; 1964; 12(1-4):133-6. PubMed ID: 16305166
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment of schizophrenia from the viewpoint of the patient. Studies on the course of treatment and neuroleptic treatment from a personal perspective].
    Windgassen K
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1989; 58():1-169. PubMed ID: 2576099
    [No Abstract]   [Full Text] [Related]  

  • 23. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?
    Gaebel W; Frick U; Köpcke W; Linden M; Müller P; Müller-Spahn F; Pietzcker A; Tegeler J
    Br J Psychiatry Suppl; 1993 Sep; (21):8-12. PubMed ID: 8105814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prognostic value of the early response of psychiatric patients to neuroleptics for the subsequent course of treatment].
    Möller HJ; Kissling W; von Zerssen D
    Pharmacopsychiatria; 1983 Mar; 16(2):46-9. PubMed ID: 6135230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia.
    Hofer A; Rettenbacher MA; Edlinger M; Kemmler G; Widschwendter CG; Fleischhacker WW
    Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zotepine in the treatment of negative symptoms in chronic schizophrenia.
    Fleischhacker WW; Barnas C; Stuppäck C; Unterweger B; Hinterhuber H
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):58-60. PubMed ID: 2883684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Latency increase of auditory-evoked potential component N1 predicts poor neuroleptic response in schizophrenic patients.
    Adler G; Markert U; Gattaz WF
    Pharmacopsychiatry; 1994 Mar; 27(2):68-9. PubMed ID: 7913236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical and typical neuroleptics in acute schizophrenia and related delusional disorders. Drug choice, switching and outcome under naturalistic treatment conditions.
    Gaebel W; Riesbeck M; Janssen B; Schneider F; Held T; Mecklenburg H; Sass H
    Eur Arch Psychiatry Clin Neurosci; 2003 Aug; 253(4):175-84. PubMed ID: 12910348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nifedipine in neuroleptic-refractory schizophrenia.
    Kramer MS; DeMaria P; Morrow R; DiJohnson C; Sheves P
    J Clin Psychopharmacol; 1987 Jun; 7(3):195-6. PubMed ID: 2885346
    [No Abstract]   [Full Text] [Related]  

  • 30. [Depressive symptoms and biogenic amines as predictors of treatment response in schizophrenic illnesses in childhood and adolescence].
    Fleischhaker C; Schulz E; Remschmidt H
    Z Kinder Jugendpsychiatr Psychother; 1998 Dec; 26(4):235-43. PubMed ID: 9880833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prolactinemia and predictability of therapeutic response of schizophrenic patients in acute decompensation].
    Vanelle JM; Amorim P; Piketti ML; Bourdel MC; Poirier-Littré MF
    Encephale; 1996 Oct; 22 Spec No 3():82-4. PubMed ID: 8954284
    [No Abstract]   [Full Text] [Related]  

  • 32. Antipsychotic effects of AL 1965.
    Sathananthan G; Mir P; Gershon S
    Curr Ther Res Clin Exp; 1976 May; 19(5):516-9. PubMed ID: 7435
    [No Abstract]   [Full Text] [Related]  

  • 33. Scales for the assessment of neuroleptic response in schizophrenic children: specific measures derived from the CPRS.
    Spencer EK; Alpert M; Pouget ER
    Psychopharmacol Bull; 1994; 30(2):199-202. PubMed ID: 7831455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Perazine therapy. Seminar, Hamburg, 12-14 November 1992].
    Nervenarzt; 1993 Jan; 64(1 Suppl):1-8. PubMed ID: 7477594
    [No Abstract]   [Full Text] [Related]  

  • 35. Binding of perazine to alpha 1-acid glycoprotein.
    Schley J; Siegert M; Müller-Oerlinghausen B
    Eur J Clin Pharmacol; 1980 Nov; 18(6):501-4. PubMed ID: 6109633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia].
    Lombertie ER; Durelle G; Fuseau A
    Ann Med Psychol (Paris); 1995 Oct; 153(8):531-4. PubMed ID: 8561400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment.
    Molero P; Ortuño F; Zalacain M; Patiño-García A
    Pharmacogenomics J; 2007 Dec; 7(6):418-26. PubMed ID: 17363961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 39. Electroencephalography in schizophrenic patients: comparison between neuroleptic-naive state and after treatment.
    Nagase Y; Okubo Y; Toru M
    Biol Psychiatry; 1996 Sep; 40(6):452-6. PubMed ID: 8879464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study.
    Möller HJ; Pelzer E; Kissling W; Riehl T; Wernicke T
    Pharmacopsychiatry; 1991 Nov; 24(6):185-9. PubMed ID: 1725925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.